For ten years, the word femtech conjured one image: a fertility app. Period trackers, ovulation predictors, conception helpers. Useful tools, genuinely needed, but they defined an entire category around a narrow window of a woman's life. The result was a sector that served half the population but kept building for the same five years.
That framing is collapsing. And the replacement is going to matter a lot if you are a mother, or becoming one, or recovering from becoming one.
The numbers stopped fitting the old story
The femtech market was valued at roughly $39 billion in 2024 and is projected to reach $97 billion by 2030. But the growth is not coming from more period trackers. It is coming from the conditions that were always there but never got funded.
Heart disease kills more women than every cancer combined. Closing the cardiovascular gap in the US alone could add an estimated $28 billion a year to the economy by 2040, plus 1.6 million quality adjusted life years. Women's health startups still pull in less than 2 percent of global venture capital despite serving half the population. That gap between the size of the problem and the size of the investment is exactly where the next wave of companies is building.
Menopause tells the same story from a different angle. Mayo Clinic researchers surveyed 4,440 working women and found that menopause symptoms cost the United States an estimated $1.8 billion a year in lost work time. That figure swells to $26.6 billion once medical expenses are included. More than a billion women worldwide will be perimenopausal or postmenopausal by 2030, and most are mid career, senior, and expensive to replace.
Employers noticed before most founders did, which is how menopause benefits went from curiosity to retention line item in about three years. The same thing is starting to happen with maternal mental health.
The conditions that were always there
Roughly 80 percent of autoimmune patients are women. A woman's lifetime risk of Alzheimer's runs close to double a man's. Women having heart attacks get misdiagnosed because their symptoms do not match a male reference model. Endometriosis, which affects one in ten women of reproductive age, still takes an average of four years to over a decade to diagnose depending on the country.
None of these fit neatly into a fertility funnel. All of them are enormous markets. And all of them intersect with motherhood in ways that the old femtech framing completely missed.
A mother who had preeclampsia has roughly double the risk of cardiovascular disease later in life. A mother with untreated postpartum depression has children who face nearly twice the risk of developing depression and anxiety as teenagers. Pregnancy is not an isolated event. It is a stress test that reveals vulnerabilities across the entire body, sometimes decades before symptoms appear.
The companies building for this wider arc are the ones reshaping what femtech means.
From symptom diaries to diagnostic infrastructure
First wave femtech was essentially a diary. You logged symptoms, the app drew a chart, and the interpretive work stayed with you. Beautiful interface, helpful tracking, but the thinking was still yours to do.
The second wave leans toward diagnosis. Models trained on continuous wearable data are starting to surface patterns tied to early pregnancy loss, thyroid dysfunction, and cardiac irregularities before a woman feels anything is wrong. A 2024 study in npj Digital Medicine tracked 120 pregnancies through a smart ring and mapped clear physiological trajectories across gestation using data the wearer was already generating every night while asleep.
This matters for maternal health in particular because the postpartum period is exactly when continuous monitoring could fill the gap between the six week checkup and the twelve month mark when most maternal mental health crises actually occur. The body is sending signals. We finally have tools that can catch them.
What this means for maternal mental health
Maternal mental health has always lived in a strange gap. It is common enough to affect one in five new mothers. It is serious enough to be the leading cause of maternal death in the year after delivery. And it has been chronically underfunded, under screened, and under treated.
The femtech market expanding beyond fertility changes this in two ways.
First, it brings capital and attention. When investors start seeing women's health as a fifty year arc rather than a fertility window, maternal mental health stops being a niche and becomes part of a continuum of care that starts before conception and extends through menopause. The total addressable market gets much bigger, and the funding follows.
Second, it brings better technology. The same AI models that flag cardiac irregularities from wearable data can be adapted to detect early signs of postpartum depression from sleep disruption, heart rate variability changes, and activity patterns. The infrastructure being built for general women's health has direct applications for the specific window when mothers are most vulnerable.
The label is starting to look like a fence
There is an active debate about whether femtech startups are the answer to women's health issues at all, or just a well designed layer over a system that still runs on male default data. Both can be true at once. A beautiful app sitting on biased clinical evidence is a beautiful mistake.
The next generation of companies has to go deeper than the interface. Into diagnostics. Into longitudinal data. Into the research pipeline itself. Into how disease behaves differently in female bodies. That is slower work, more regulated, more capital hungry than shipping a tracker. It is also where the defensible value lives.
For mothers, this shift cannot come fast enough. The conditions that complicate pregnancy, that linger after birth, that compound across decades of caregiving, are the same conditions that the old femtech framing ignored. A market that finally takes them seriously is not just a bigger market. It is a better one.
The future of femtech will be decided outside the delivery room. For mothers who have been carrying the mental load, the physical recovery, and the long tail of postpartum health with almost no support, that future cannot come soon enough.
AlphaMa is building the AI companion for that in between space. The months after the baby comes, when the app notifications stop and the support falls away. The kind of tool that meets a mother where she is, at midnight, when the only other thing awake is her phone.
Related reading: